Vaccine Clinical Trials are a critical step in the development and evaluation of new vaccines, ensuring their safety, efficacy, and effectiveness before they are approved for widespread use. These trials involve rigorous testing in human volunteers to assess the vaccine's ability to stimulate an immune response, prevent disease, and minimize adverse effects. The vaccine development process typically begins with preclinical studies, where candidate vaccines are tested in laboratory and animal models to evaluate their safety and immunogenicity. Promising candidates then progress to clinical trials, which consist of three phases:
Phase I trials: These trials involve a small number of healthy volunteers and focus on assessing the vaccine's safety, dosage, and immunogenicity. Phase II trials: These trials enroll a larger number of volunteers and further evaluate the vaccine's safety, immunogenicity, and dosage. Participants may include individuals from diverse demographics, such as different age groups or risk factors. Phase III trials: These trials are large-scale, randomized, controlled studies that assess the vaccine's efficacy and safety in real-world conditions. Participants are randomly assigned to receive either the vaccine or a placebo, and researchers measure the incidence of disease in both groups to determine the vaccine's effectiveness.
Throughout each phase of clinical trials, participants are closely monitored for adverse events, and data is collected to assess the vaccine's safety, efficacy, and immunogenicity. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), review the trial data and determine whether to grant approval for the vaccine's licensure. After approval, post-marketing surveillance continues to monitor the vaccine's safety and effectiveness in real-world settings. This ongoing monitoring helps detect rare or long-term side effects that may not have been identified during clinical trials.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe